Glofitamab

格菲妥单抗

Report date: 2026/04/15 20:02:38

Base Information

Drug NameGlofitamab
Drug Alias NameaCD20/CD3-TCBs格罗菲妥单抗aCD20/CD3-TCB 2CD20-TCBglofitamab-gxbm +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD20T-cell surface glycoprotein CD3 epsilon chain modulatorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsB-lymphocyte antigen CD20T-cell surface glycoprotein CD3 epsilon chain
Therapy Area/IndicationsCentral Nervous System LymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Global Approved IndicationsLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaLymphoma, Large B-Cell, Diffuse
Original Approved Country/TerritoryCanada
Original Approved Date2023/03/25
Country/TerritoryCzechiaBelgiumCanada +[25] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesF. Hoffmann-La Roche Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRoche Pharma AgRoche Pharma (Schweiz) AgF. Hoffmann-La Roche Ag +[10] 
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsCentral Nervous System LymphomaLymphoma, Mantle-CellLymphoma, Follicular +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL01FX
Related LinksDrugBankKEGG